This company listing is no longer active
Halo Collective Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Halo Collective's earnings have been declining at an average annual rate of -37.9%, while the Pharmaceuticals industry saw earnings growing at 26.5% annually. Revenues have been growing at an average rate of 11.7% per year.
Información clave
-37.9%
Tasa de crecimiento de los beneficios
66.1%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 23.1% |
| Tasa de crecimiento de los ingresos | 11.7% |
| Rentabilidad financiera | -367.4% |
| Margen neto | -393.9% |
| Última actualización de beneficios | 30 Jun 2023 |
Actualizaciones de resultados anteriores recientes
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero Halo Collective. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 23 | 18 | -72 | 25 | 0 |
| 31 Mar 23 | 22 | -76 | 32 | 0 |
| 31 Dec 22 | 25 | -84 | 36 | 0 |
| 30 Sep 22 | 28 | -95 | 38 | 0 |
| 30 Jun 22 | 32 | -99 | 43 | 0 |
| 31 Mar 22 | 34 | -99 | 44 | 0 |
| 31 Dec 21 | 36 | -95 | 42 | 0 |
| 30 Sep 21 | 33 | -54 | 39 | 0 |
| 30 Jun 21 | 31 | -47 | 31 | 0 |
| 31 Mar 21 | 27 | -42 | 25 | 0 |
| 31 Dec 20 | 22 | -41 | 22 | 0 |
| 30 Sep 20 | 19 | -33 | 24 | 0 |
| 30 Jun 20 | 20 | -35 | 27 | 0 |
| 31 Mar 20 | 24 | -33 | 26 | 0 |
| 31 Dec 19 | 28 | -28 | 24 | 0 |
| 30 Sep 19 | 28 | -17 | 17 | 0 |
| 30 Jun 19 | 25 | -17 | 14 | 0 |
| 31 Mar 19 | 17 | -15 | 11 | 0 |
| 31 Dec 18 | 11 | -14 | 9 | 0 |
| 30 Sep 18 | 10 | -15 | 11 | 0 |
| 30 Jun 18 | 10 | -11 | 10 | 0 |
| 31 Mar 18 | 10 | -10 | 10 | 0 |
| 31 Dec 17 | 10 | -9 | 9 | 0 |
| 31 Dec 16 | 5 | 0 | 1 | 0 |
Ingresos de calidad: HALO is currently unprofitable.
Margen de beneficios creciente: HALO is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: HALO is unprofitable, and losses have increased over the past 5 years at a rate of 37.9% per year.
Acelerando crecimiento: Unable to compare HALO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: HALO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (77.9%).
Rentabilidad financiera
Alta ROE: HALO has a negative Return on Equity (-367.44%), as it is currently unprofitable.